Key Developments: IRIDEX Corp (IRIX.OQ)
6.20USD
1 Aug 2013
$0.00 (+0.00%)
$6.20
$6.10
$6.20
$6.09
1,000
5,301
$6.57
$3.10
Latest Key Developments (Source: Significant Developments)
Iridex Corporation Issues Q3 2013 Revenue Guidance
Iridex Corporation announced that for the third quarter of 2013, it expects to achieve revenue between $8.8 million and $9.1 million. Full Article
Iridex Corporation Issues Q2 2013 Revenue Guidance
Iridex Corporation announced that for the second quarter 2013, it expects to achieve revenues between $8.9 million and $9.2 million. Full Article
Iridex Corporation Announces Global Distribution And Supply Agreement With Peregrine Surgical Ltd
Iridex Corporation announced that it has entered into a global distribution and supply agreement with Peregrine Surgical, Ltd., a privately held company based in New Britain, Pennslvania. Under the agreement, IRIDEX will become a worldwide distributor for Peregrine labeled products and Peregrine Surgical will become part of the IRIDEX supply chain for the manufacture of certain IRIDEX products. Full Article
Iridex Corporation Issues Q1 2013 Revenue Guidance
Iridex Corporation announced that for the first quarter of 2013, it expects to achieve revenues of between $8.7 million and $9.0 million. Full Article
Iridex Corporation Announces Tender Offer To Purchase Up To 487,500 Shares Of Its Common Stock
Iridex Corporation announced that it expects to commence a tender offer to purchase up to 487,500 shares of its common stock at a purchase price of $4.10 per share. The number of shares proposed to be purchased in the tender offer represents approximately 5.5% of IRIDEX's issued and outstanding shares of common stock. The last reported sale price of shares of IRIDEX common stock on the NASDAQ Global Market on November 6, 2012 was $3.92 per share. The tender offer will commence on November 7, 2012 and is scheduled to expire at 5:00p.m., New York City time, on December 7, 2012, unless extended. Tenders of shares must be made prior to the expiration of the tender offer and may be withdrawn at any time prior to the expiration of the tender offer. The tender offer is not contingent upon any minimum number of shares being tendered. The tender offer is, however, subject to a number of terms and conditions. The terms and conditions of the tender offer will be described in the offer to purchase (the Offer to Purchase) and related letter of transmittal (the Letter of Transmittal) to be distributed to holders of IRIDEX common stock. On the terms and subject to the conditions of the tender offer, IRIDEX's stockholders will have the opportunity to tender some or all of their shares at a price of $4.10 per share, net to the seller in cash, less any applicable withholding taxes and without interest. All shares accepted in the tender offer will be purchased at the same price per share. Full Article
Iridex Corporation Issues Q4 2012 Revenue Guidance
Iridex Corporation announced that for the fourth quarter of 2012, it expects to achieve revenues between $8.4 million and $8.7 million. Full Article
Iridex Corporation Appoints Chairman William M. Moore As Interim President And Chief Executive Officer
Iridex Corporation announced that Board of Directors has named medical device industry veteran William M. Moore., as Interim President and Chief Executive Officer, effective immediately. Moore replaces Dominik Beck, whose employment with the Company ceased on August 24, 2012. Full Article
IRIDEX Corporation Issues Q3 2012 Revenue Guidance
IRIDEX Corporation announced that for the third quarter of 2012, it expects to achieve revenue between $8.4-$8.8 million. Full Article
IRIDEX Corporation Issues Q2 2012 Revenue Guidance
IRIDEX Corporation announced that for second quarter of 2012, it expects evenue between $8.5 million and $8.8million. Full Article
IRIDEX Corporation Issues Q1 2012 Revenue Guidance-Conference Call
IRIDEX Corporation announced that for the first quarter of 2012, it expects revenues to be in the range of $8.5 million to $8.8 million. Full Article

Earnings vs.
Estimates